The schizophrenia market is expected to showcase significant growth driven by rising disease prevalence, the expanding market for approved therapies, and the anticipated launch of new schizophrenia treatments such as Olanzapine LAI (TEV-44749/mdc-TJK; Teva Pharmaceutical/MedinCell/Royalty Pharma), Ulotaront (SEP-363856; Sumitomo Pharma/Otsuka Pharmaceuticals), Brilaroxazine (RP-5063; Reviva Pharmaceuticals), and others during the forecast period.
LAS VEGAS, Oct. 7, 2026 /PRNewswire/ — Recently published Schizophrenia Market Insights report includes a comprehensive understanding of current treatment practices, emerging schizophrenia drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Discover FDA approved medications for schizophrenia with brand and generic names 2026 @ https://www.delveinsight.com/report-store/schizophrenia-market
Key Factors Driving the Growth of the Schizophrenia Market
Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that the market for schizophrenia drugs is driven by increasing demand for long-acting antipsychotic medications, along with the emergence of new molecules in development.
Some of the schizophrenia medications under development include Olanzapine LAI (TEV-44749/mdc-TJK; Teva Pharmaceutical/MedinCell/Royalty Pharma), Ulotaront (SEP-363856; Sumitomo Pharma/Otsuka Pharmaceuticals), Brilaroxazine (RP-5063; Reviva Pharmaceuticals), Roluperidone (MIN-101/MT-210; Minerva Neurosciences/Mitsubishi Tanabe Pharma), Evenamide (NW-3509; Newron Pharmaceuticals), NBI-570 (Neurocrine Biosciences/Nxera Pharma), LB-102 (LB Pharmaceuticals), and others.
Teva Pharmaceutical/MedinCell/Royalty Pharma’s TEV-‘749 (olanzapine) is an investigational, once-monthly, long-acting subcutaneous formulation of the second-generation antipsychotic olanzapine. The product has not received regulatory approval for any indication, and its safety and efficacy have yet to be established. Teva’s schizophrenia portfolio has advanced with the development of TEV-‘749, a once-monthly subcutaneous long-acting injectable formulation designed to provide sustained olanzapine treatment.
Sumitomo Pharma/Otsuka Pharmaceuticals’ Ulotaront (SEP-363856) is an investigational small-molecule, orally administered trace amine-associated receptor 1 (TAAR1) agonist that also exhibits serotonin 5-HT1A agonist activity. Unlike conventional antipsychotics, ulotaront does not bind to dopamine D2 or serotonin 5-HT2A receptors. The drug is being jointly developed and commercialized through a collaboration among Sumitomo Pharma, its U.S. subsidiary Sumitomo Pharma America (SMPA), and Otsuka. SMPA discovered ulotaront in collaboration with PsychoGenics, leveraging a mechanism-independent discovery strategy based partly on the in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms.
Reviva Pharmaceuticals’ Brilaroxazine (RP-5063) is a novel chemical entity with potent affinity and selectivity for key serotonin and dopamine receptors implicated in schizophrenia and other psychiatric disorders. The compound acts as a multimodal modulator of serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT7 receptors, as well as dopamine D2, D3, and D4 receptors, and is undergoing clinical development across multiple neuropsychiatric indications. In addition to schizophrenia, brilaroxazine is being investigated for bipolar disorder, major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), and inflammatory conditions, including pulmonary arterial hypertension, idiopathic pulmonary fibrosis, and psoriasis.
Minerva Neurosciences/Mitsubishi Tanabe Pharma’s Roluperidone (MIN-101) is being developed by Minerva Neurosciences for the treatment of persistent negative symptoms of schizophrenia, which can remain chronic and substantially affect patients’ quality of life and functional outcomes. The drug acts on serotonin and sigma receptors in the brain, which are associated with the regulation of mood, cognition, sleep, and anxiety. Minerva Neurosciences holds a global license for roluperidone from Mitsubishi Tanabe Pharma Corporation, including rights to develop, commercialize, and import the compound, also known as MT-210. Roluperidone has completed Phase III clinical development in the U.S. for the treatment of negative symptoms associated with schizophrenia.
The anticipated launch of these emerging therapies are poised to transform the schizophrenia market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the schizophrenia market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the schizophrenia drugs market @ Schizophrenia Therapies
Recent Developments in the Schizophrenia Market
The schizophrenia epidemiology section provides insights into the historical and current schizophrenia patient pool and forecasted trends for the leading markets. Most schizophrenia patients globally do not receive mental health care. Around 50% of mental hospital patients have schizophrenia, but only 31.3% of those with psychosis receive specialized care.
The schizophrenia treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Teva Pharmaceutical, MedinCell, Royalty Pharma, Sumitomo Pharma, Otsuka Pharmaceuticals, Reviva Pharmaceuticals, Minerva Neurosciences, Mitsubishi Tanabe Pharma, Newron Pharmaceuticals, Neurocrine Biosciences, Nxera Pharma, LB Pharmaceuticals, Janssen Pharmaceuticals, Alkermes, Luye Pharma, Vanda Pharmaceuticals, Intra-cellular Therapies, Gedeon Richter, AbbVie, Bristol Myers Squibb (Karuna Therapeutics), Zia Labs, and others
Olanzapine LAI (TEV-44749/mdc-TJK), Ulotaront (SEP-363856), Brilaroxazine (RP-5063), Roluperidone (MIN-101/MT-210), Evenamide (NW-3509), NBI-570, LB-102, REXULTI/RXULTI, CAPLYTA, LONASEN, ABILIFY MYCITE, UZEDY, FANAPT, LYBALVI, COBENFY, and others
Download the report to understand medications used to treat schizophrenia @ Schizophrenia Clinical Trials
Gender-specific Diagnosed Prevalent Cases of Schizophrenia
Severity-specific Diagnosed Prevalent Cases of Schizophrenia
Total Prevalent Cases of Schizophrenia in the 7MM
Total Diagnosed Prevalent Cases of Schizophrenia in the 7MM
Total Prevalent Cases of Schizophrenia in the US
Total Diagnosed Prevalent Cases of Schizophrenia in the US
Gender-specific Diagnosed Prevalent Cases of Schizophrenia in the US
Severity-specific Diagnosed Prevalent Cases of Schizophrenia in the US
INVEGA SUSTENNA (XEPLION)/INVEGA TRINZA (TREVICTA)/INVEGA HAFYERA (BYANNLI) (paliperidone palmitate): Janssen Pharmaceuticals
UZEDY (risperidone): Teva Pharmaceuticals/MedinCell
RISPERDAL CONSTA (risperidone, long-acting): Alkermes/Janssen Pharmaceuticals
ABILIFY ASIMTUFII (aripiprazole): Otsuka Pharmaceutical/Lundbeck
REXULTI/RXULTI (brexpiprazole): Otsuka Pharmaceutical/H. Lundbeck
CAPLYTA (lumateperone/ITI-007): Intra-cellular Therapies
VRAYLAR/REAGILA (cariprazine): Gedeon Richter/AbbVie
LYBALVI (olanzapine and samidorphan): Alkermes
ARISTADA and ARISTADA INITIO (aripiprazole lauroxil): Alkermes
PERSERIS (risperidone): DURECT Corporation/Indivior
SECUADO (asenapine/HP-3070): Noven Pharmaceuticals/Hisamitsu Pharmaceutical
LATUDA (lurasidone hydrochloride): Sunovion Pharmaceuticals/Sumitomo Dainippon Pharma
COBENFY (xanomeline–trospium): Bristol Myers Squibb (Karuna Therapeutics)/Royalty Pharma/Zia Labs
Olanzapine LAI (TEV-44749/mdc-TJK): Teva Pharmaceutical/MedinCell/Royalty Pharma
Ulotaront (SEP-363856): Sumitomo Pharma/Otsuka Pharmaceuticals
Brilaroxazine (RP-5063): Reviva Pharmaceuticals
Roluperidone (MIN-101/MT-210): Minerva Neurosciences/Mitsubishi Tanabe Pharma
Key Schizophrenia Market Forecast Assumptions
Total Market Size of Schizophrenia in the 7MM
Total Market Size of Schizophrenia by Therapies in the 7MM
The Market Size of Schizophrenia by Therapies in the US
Market Size of Schizophrenia in EU4 and the UK
Schizophrenia Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key schizophrenia companies, including Sunovion Pharmaceuticals, Denovo BioPharma, Cyclerion Therapeutics, Karuna Therapeutics, Boehringer Ingelheim, Merck Sharp & Dohme, MapLight Therapeutics, Valentech LLC, Addex Therapeutics, Biodexa Pharmaceuticals, Autifony Therapeutics, Vanda Pharmaceuticals, Luye Pharma, Reviva Pharmaceuticals, SyneuRx, Avanir Pharmaceuticals, Newron Pharmaceuticals, Celon Pharma, Delpor, Zhejiang Jingxin Pharmaceutical, Sirtsei Pharmaceuticals, and others.
Cognitive Impairment Associated with Schizophrenia Market
Cognitive Impairment Associated with Schizophrenia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key cognitive impairment associated with schizophrenia companies, including Boehringer Ingelheim, Recognify Life Sciences, Alto Neuroscience, MEDRx, Kynexis, Gabather AB, and others.
Bipolar Depression Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bipolar depression companies, including Xenon Pharmaceuticals, Autobahn Therapeutics, AbbVie, Alto Neuroscience, NRx Pharmaceuticals, LB Pharmaceuticals, and others.
Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer’s disease companies, including ARS Pharmaceuticals, Alfresa Pharma, Roche, Stallergenes Greer, DBV Technologies, Aquestive Therapeutics, Aravax, Siolta Therapeutics, GSK, Cue Biopharma, N-Fold, InnoUp Farma, Allergy Therapeutics, UKKO, Bryn Pharma, Poplar Therapeutics, Inimmune, Novartis (Excellergy), Intrommune Therapeutics, Regeneron Pharmaceuticals, Sanofi, Moonlight Therapeutics, Mabylon AG, Insignis Therapeutics, ALK-Abello, Cambridge Allergy, Prota Therapeutics, and others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
